Protagonist Therapeutics (NASDAQ:PTGX) Given New $118.00 Price Target at Jefferies Financial Group

Protagonist Therapeutics (NASDAQ:PTGX) had its price target upped by equities research analysts at Jefferies Financial Group from $95.00 to $118.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 42.08% from the company’s current price.

Other research analysts also recently issued research reports about the company. BTIG Research reaffirmed a “buy” rating and issued a $82.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Wedbush upped their price target on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Truist Financial lifted their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. HC Wainwright boosted their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday. Finally, Citizens Jmp raised their target price on Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $91.64.

Protagonist Therapeutics Price Performance

NASDAQ PTGX traded up $1.25 on Monday, reaching $83.05. The stock had a trading volume of 1,414,660 shares, compared to its average volume of 889,415. The firm has a fifty day moving average of $86.26 and a two-hundred day moving average of $72.95. Protagonist Therapeutics has a 1-year low of $33.70 and a 1-year high of $96.54. The company has a market cap of $5.19 billion, a P/E ratio of 133.95 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total value of $410,000.00. Following the completion of the transaction, the insider directly owned 84,115 shares in the company, valued at approximately $6,897,430. This represents a 5.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Asif Ali sold 46,203 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the transaction, the chief financial officer owned 60,320 shares in the company, valued at approximately $5,014,401.60. This trade represents a 43.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 165,167 shares of company stock valued at $13,732,039 in the last ninety days. 4.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at about $29,000. FNY Investment Advisers LLC bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $27,000. Bessemer Group Inc. grew its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after purchasing an additional 318 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.